Susumé
Continuously blocks the transmission of bacteria
Contributing to infectious disease prevention with solid evidence
We aim to contribute to society through specialized infection control measures.
Updated September 1, 2024
The spread of infectious diseases has occurred many times in the past, resulting in many deaths.
Infectious diseases are difficult to solve and are considered to be an eternal challenge for humankind. Many infectious diseases occur in poor living environments, and my previous experience with a JICA project led me to get involved in infectious diseases.
Infectious diseases can be transmitted through the air, droplets, or contact, but it is generally believed that about 80% of infections are caused by bacteria and viruses transmitted through contact. Therefore, if we can continuously block transmission, we can significantly reduce the number of infections.
Unlike conventional antibacterial agents, the newly developed antibacterial agent is a solid bactericidal agent, so it is characterized by its continuity, non-toxicity, and no elution, so there is no environmental impact. In the future, there are many possible uses for this product, not only in the medical field, but also in food hygiene management, water and air, etc., but we have decided to focus our business on infectious disease control.
The business model will be a licensing business centered on the supply of the antibacterial agent "AbedulAg+."
access
Susumé Co., Ltd
Address
09-00-39 Shirakabadaira Mitsuinomori Tateshinakogen, Chino, Nagano 391-0213 JAPAN
CEO
Tsukasa Sakurada
contact
Latest News
◎ September 6, 2025
Continuous Antimicrobial Technology "AbedulAg+" for Infection Prevention
～Scientific Validation and Exploration of Technical Possibilities～
How to Confront Infections Caused by Drug-Resistant Bacteria?
Please enter from "How to Combat Infections Caused by Drug-Resistant Bacteria?"
at the top of the homepage. You can view the details there.
Table of Contents
1, Why did we choose textiles as a commercial product?
2, Why do we focus on drug-resistant bacteria in infectious diseases?
3, Understanding the current status of infections caused by drug-resistant bacteria (Japan-US comparison)
a) Severity b) Current status of nosocomial infections c) Drug-resistant bacteria to be aware of d) Policy comparison
4, Why are infectious diseases said to be humanity's eternal challenge?
5, In 2008, the U.S. EPA approved copper alloys as continuous antimicrobial agents for the first time in the world.
(Posted on November 19, 2025)
a) Proposed physical contact disinfection rather than pharmaceutical administration.
b) Clinically demonstrated effectiveness against multidrug-resistant bacteria such as MRSA and VRE.
6, Reasons for Using Silver Ions as Active Species (Posted January 20, 2026)
7, Challenges of Conventional Silver-based Antimicrobial Agents and New Proposals (Posted January 21, 2026)
8, Advantages of the silver ion disinfection mechanism (posted March 7, 2026)
9, Advantages of Silver Ion Disinfection in the Medical Field (Submitted on March 11, 2026)
10, Absolute Advantages of Silver Ion Disinfection in Terms of Safety (Submitted on March 11, 2026)
11, Superiority of silver ion sterilization in terms of environmental safety (Posted March 13, 2026)
12, Economic Advantages of Silver Ion Antimicrobial Technology (Posted March 15, 2026)
13, Technical Advantages of the Electrolytic Silver Ion Long-Lasting Antimicrobial Agent “AbedulAg⁺” (Posted on
March 20, 2026)
14, Fourteen years ago, copper alloys were approved by the U.S. Environmental Protection Agency (EPA)
as persistent antimicrobial materials. Subsequently, the world’s first clinical trial demonstrated that
infection prevention could be achieved with a statistically significant probability of 58%, leading to the
publication of numerous academic papers. However, despite these promising results, practical
implementation has stagnated. In this study, we examine the underlying reasons for this limited
adoption by comparing copper-based systems with our newly developed persistent antimicrobial agent,
“AbedulAg⁺.” (Posted on March 21, 2026)
15. Strategic importance of sustained-release fungicides (Posted March 31, 2026)
16. The importance of research on infectious diseases (Posted April 19, 2026)
.png){kind=small}